Select Page
  1. Home
  2.  » 
  3. Events
  4.  » PEGS Boston

PEGS Boston

Schedule a Meeting with Catalent at PEGS Boston

Dates: August 31- September 4, 2020

Location: Virtual Conference


Greg Bleck, PhD
Global Head of R&D, Biologics
Session Track: Optimizing Protein Expression – BIOCONJUGATE STREAM
Date/Time: Wednesday, September 2, 2020 at 9:45 AM – 10:15 AM (EST)



Robyn Barfield, PhD
Group Leader, Chemical Biology, Catalent
Session Title: Novel SMARTagTM linkers enable better-tolerated ADCs with potential for a wider clinical therapeutic index relative to approved therapies
Date/Time: Wednesday, September 2, 2020 at 3:05PM – 3:30PM (EST)


Abstract: Catalent’s SMARTag™ technology uses a simple, robust manufacturing process to generate stable, site-specific ADCs. Our RED-106 noncleavable maytansine linker-payload is well-tolerated and resistant to P-glycoprotein efflux, offering wider therapeutic windows as compared to other technologies. This advantage is illustrated by our anti-HER2 RED-106 ADC in comparison to the related drug, T-DM1. Our dual-release cleavable MMAE linker system enables serum stability not seen with other technologies, leading to ADCs with superior tolerability relative to related drugs carrying the VC-PABC-MMAE linker-payload.


A Novel HER2-Targeted Antibody-Drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-Equivalent Exposure Levels
Robyn Barfield, PhD, Group Leader, Chemical Biology, Catalent